<DOC>
	<DOCNO>NCT00995566</DOCNO>
	<brief_summary>The Thelin Patient Safety Registry post-marketing program European Union ( EU ) design supplement report spontaneous adverse event ( AE ) good characterize know potential safety signal Thelin . The registry secure , restrict access , electronic system collect anonymous , pre-defined , patient-level data demographic variable , safety monitoring measurement ( i.e . liver function test , haemoglobin international normalize ratio ( INR ) measurement ) , concomitant medication , information AEs Thelin drug discontinuation . Regular review data conduct assess frequency identify safety risk monitor emergence new safety signal monthly pharmacovigilance meeting , quarterly signal detection meeting , Periodic Safety Update Report ( PSUR ) .</brief_summary>
	<brief_title>A Non-Interventional , Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin</brief_title>
	<detailed_description>Non-probability sample</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>Evidence personally sign date informed consent document patient indicate he/she ( legally acceptable representative ) inform pertinent aspect study requirement inclusion . Additional inclusion criterion reflect approve label Thelin outline SmPC . There specific exclusion criterion enrollment Thelin Patient Safety Registry , exception reflect approved label Thelin outline SmPC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>